BioCentury | Mar 5, 2020
Emerging Company Profile

AiCure: harnessing AI to boost adherence

AiCure is combining a decade’s worth of research into real-world patient behavior with an artificial intelligence platform to optimize patient adherence to treatments in clinical trials. Lack of patient compliance to long-term treatments can lead...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting inflammatory macrophages could help treat Type II diabetes-associated pain. In a mouse model of Type II diabetes, the macrophage-targeting immunotoxin Mac1-saporin decreased disease-induced mechanical allodynia compared with vehicle. Also...
BioCentury | Nov 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Adenocarcinoma; brain cancer; lung cancer; neuroendocrine tumors Cell culture studies identified a nicotonic acetylcholine receptor α7 (CHRNA7) antagonist that could help treat glioblastoma, lung adenocarcinoma and neuroblastoma. Chemical synthesis and cell-based testing of structural...
BioCentury | Oct 26, 2018
Company News

Stanford launches cannabinoid company Katexco for inflammatory disorders

Stanford University professors launched Katexco Pharmaceuticals Corp. (Toronto, Ontario) to develop therapies that target endocannabinoid and nicotine receptors to treat inflammatory diseases. Katexco has exclusively licensed IP from the university. The IP was generated by...
BioCentury | Oct 5, 2018
Clinical News

Bionomics discontinues BNC210 for PTSD after Phase II miss

Bionomics Ltd. (ASX:BNO; OTCQX;BNOEF) discontinued development of BNC210 to treat posttraumatic stress disorder (PTSD) after the compound missed the primary endpoint in the Phase II RESTORE trial in the indication. Twice-daily oral BNC210 did not...
BioCentury | May 4, 2018
Financial News

Attenua raises $35M series A

Cough company Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round on April 30 in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and...
BioCentury | Apr 30, 2018
Financial News

Cough company Attenua raises $35M series A, names CEO

Attenua Inc. (Mountain View, Calif.) raised $35 million in a series A round led by new investor Omega Funds. New investors Abingworth, OrbiMed Advisors and Redmile Group also participated. Attenua plans to start Phase II...
BioCentury | Feb 16, 2017
Company News

Bionomics, Merck deal

Bionomics will receive a $10 milestone payment from Merck under a 2014 deal granting the pharma exclusive, worldwide development and commercialization rights to Bionomics’ BNC375 program, which targets cognitive dysfunction associated with Alzheimer’s disease and...
BioCentury | Dec 13, 2016
Distillery Therapeutics

Inflammation

INDICATION: Asthma Cell culture and mouse studies suggest CHRNA7 agonists could help treat allergic asthma. In a mouse model of airway hyperresponsiveness, intranasal administration of a CHRNA7 agonist tool compound decreased airway resistance and dynamic...
BioCentury | Oct 31, 2016
Company News

Catalyst Biosciences deal

Catalyst will sell TC-6499 to an undisclosed buyer for $750,000 up front and up to $37 million in milestones, plus undisclosed royalties. Catalyst, which gained the products when it merged with Targacept Inc. , declined to...
Items per page:
1 - 10 of 217